Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.

Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells.

Dang Y, Wagner WM, Gad E, Rastetter L, Berger CM, Holt GE, Disis ML.

Clin Cancer Res. 2012 Jun 1;18(11):3122-31. doi: 10.1158/1078-0432.CCR-12-0113. Epub 2012 Apr 17.

2.
3.

TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells.

Narusawa M, Inoue H, Sakamoto C, Matsumura Y, Takahashi A, Inoue T, Watanabe A, Miyamoto S, Miura Y, Hijikata Y, Tanaka Y, Inoue M, Takayama K, Okazaki T, Hasegawa M, Nakanishi Y, Tani K.

Cancer Immunol Res. 2014 Jun;2(6):568-80. doi: 10.1158/2326-6066.CIR-13-0143. Epub 2014 Apr 10.

4.

Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.

Fernández A, Oliver L, Alvarez R, Fernández LE, Lee KP, Mesa C.

Hum Vaccin Immunother. 2014;10(11):3251-60. doi: 10.4161/hv.29847. Review.

5.

Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists.

Triozzi PL, Aldrich W, Ponnazhagan S.

Vaccine. 2010 Nov 23;28(50):7837-43. doi: 10.1016/j.vaccine.2010.09.086. Epub 2010 Oct 27.

PMID:
20937315
6.

Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.

Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S, Cheever MA.

Blood. 1996 Jul 1;88(1):202-10.

7.

Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.

Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A.

Cancer Res. 2001 Nov 1;61(21):7925-33.

8.

Induction of homologous rather than heterologous antigen-specific CD4 T cell responses is critical for functional CD8 T cell responses in mice transgenic for a foreign antigen.

Sabarth N, Chamberlain L, Brett S, Tite J, Craigen J.

J Immunol. 2010 Oct 15;185(8):4590-601. doi: 10.4049/jimmunol.0803994. Epub 2010 Sep 22.

9.

The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.

Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, Miller JF, Liau LM.

J Immunol. 2006 Jan 1;176(1):157-64.

10.

Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma.

Ho MY, Sun GH, Leu SJ, Ka SM, Tang SJ, Sun KH.

Int J Cancer. 2008 Jul 1;123(1):123-33. doi: 10.1002/ijc.23474.

11.

The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.

Int J Oncol. 2006 Apr;28(4):947-53.

PMID:
16525645
12.

Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice.

Wang X, Dong A, Xiao J, Zhou X, Mi H, Xu H, Zhang J, Wang B.

Cell Mol Immunol. 2016 Nov;13(6):850-861. doi: 10.1038/cmi.2015.64. Epub 2015 Jul 13.

13.

Suppressive effects on the immune response and protective immunity to a JEV DNA vaccine by co-administration of a GM-CSF-expressing plasmid in mice.

Chen H, Gao N, Fan D, Wu J, Zhu J, Li J, Wang J, Chen Y, An J.

PLoS One. 2012;7(4):e34602. doi: 10.1371/journal.pone.0034602. Epub 2012 Apr 6.

14.

Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants.

Ali OA, Verbeke C, Johnson C, Sands RW, Lewin SA, White D, Doherty E, Dranoff G, Mooney DJ.

Cancer Res. 2014 Mar 15;74(6):1670-81. doi: 10.1158/0008-5472.CAN-13-0777. Epub 2014 Jan 30.

15.

Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Nakamori M, Ueda K, Naka T, Ishida K, Primus FJ, Yamaue H.

Int J Cancer. 2007 Feb 1;120(3):585-93.

16.
18.

Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides.

Scheibenbogen C, Schadendorf D, Bechrakis NE, Nagorsen D, Hofmann U, Servetopoulou F, Letsch A, Philipp A, Foerster MH, Schmittel A, Thiel E, Keilholz U.

Int J Cancer. 2003 Mar 20;104(2):188-94.

19.

Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects.

Bowne WB, Wolchok JD, Hawkins WG, Srinivasan R, Gregor P, Blachere NE, Moroi Y, Engelhorn ME, Houghton AN, Lewis JJ.

Cytokines Cell Mol Ther. 1999 Dec;5(4):217-25.

PMID:
10850386
20.

Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant.

Engel AL, Sun GC, Gad E, Rastetter LR, Strobe K, Yang Y, Dang Y, Disis ML, Lu H.

Immunobiology. 2013 Dec;218(12):1468-76. doi: 10.1016/j.imbio.2013.05.001. Epub 2013 May 13.

Supplemental Content

Support Center